ResMed Inc. (NYSE: RMD) director sells 8,000 shares under 10b5-1 plan

Rhea-AI Filing Summary

ResMed Inc. director Peter C. Farrell reported selling 8,000 shares of ResMed Common Stock on 2026-08-05 at $225.00 per share in an open-market or private transaction. The sale was conducted under a Rule 10b5-1 plan adopted August 12, 2025.

After this transaction, Farrell directly holds 52,773 shares of ResMed Common Stock.

Insider Trade Summary 10b5-1

Net Seller: 8,000 shares

Net Sell 1 txn

Insider FARRELL PETER C

Role Director

Sold 8,000 shs ($1.80M)

Type	Security	Shares	Price	Value
Sale	ResMed Common Stock F1	8,000	$225.00	$1.80M

Holdings After Transaction: ResMed Common Stock — 52,773 shares (Direct)

Footnotes (1)

1. F1. The transaction was conducted under a Rule 10b5-1 plan adopted August 12, 2025.

Key Figures

Shares sold: 8,000 shares Sale price per share: $225.00 Shares held after transaction: 52,773 shares +1 more

4 metrics

Shares sold 8,000 shares ResMed Common Stock sold on 2026-08-05

Sale price per share $225.00 Price per share for the 8,000-share sale

Shares held after transaction 52,773 shares Direct ownership of ResMed Common Stock following the sale

Rule 10b5-1 plan adoption date August 12, 2025 Adoption date of the trading plan governing this sale

Key Terms

Rule 10b5-1 plan, open market or private transaction, ResMed Common Stock

3 terms

Rule 10b5-1 plan regulatory

"The transaction was conducted under a Rule 10b5-1 plan adopted August 12, 2025."

A Rule 10b5-1 plan is a prearranged, written schedule that lets corporate insiders buy or sell company stock at set times or amounts, even if they later learn material nonpublic information. Think of it like setting an automatic thermostat for trades: it creates a clear record that trades were planned in advance, reducing the risk of insider-trading accusations and helping investors trust that insider transactions are routine rather than based on secret information.

open market or private transaction financial

"Transaction code description: Sale in open market or private transaction."

ResMed Common Stock financial

"Security title reported as ResMed Common Stock in the transaction."

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Form 4 Insider Transactions: What Each Field Means →

Available on EDGAR 08/06/2026 - 02:30 PM Accepted by SEC EDGAR 08/06/2026 - 02:29 PM Learn about SEC filing dates

FAQ

What insider stock sale did ResMed (RMD) director Peter C. Farrell report?

Peter C. Farrell reported selling 8,000 shares of ResMed Common Stock at $225.00 per share on 2026-08-05. The transaction was an open-market or private sale executed under a pre-arranged Rule 10b5-1 trading plan.

How many ResMed (RMD) shares does Peter C. Farrell hold after the reported sale?

After the sale, Peter C. Farrell directly holds 52,773 shares of ResMed Common Stock. This figure reflects his reported direct ownership immediately following the 8,000-share disposition on 2026-08-05.

At what price were the ResMed (RMD) shares sold in Peter C. Farrell’s Form 4?

The reported sale price was $225.00 per share for 8,000 shares of ResMed Common Stock. The transaction is described as a sale in an open-market or private transaction, executed pursuant to a Rule 10b5-1 trading plan.

Was Peter C. Farrell’s ResMed (RMD) stock sale made under a Rule 10b5-1 plan?

Yes. The footnote states the transaction was conducted under a Rule 10b5-1 plan adopted on August 12, 2025. Such plans pre-arrange trading activity according to specified instructions set in advance.

What type of transaction is shown in Peter C. Farrell’s ResMed (RMD) Form 4?

The Form 4 reports a sale of common stock, coded “S” as a non-derivative transaction. It is characterized as a sale in an open-market or private transaction, with 8,000 shares disposed at $225.00 per share.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

X

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

FARRELL PETER C

(Last) (First) (Middle)

9001 SPECTRUM CENTER BLVD.

(Street)

SAN DIEGO CALIFORNIA 92123

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
RESMED INC [ RMD ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
08/05/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
ResMed Common Stock	08/05/2026		S(1)		8,000	D	$225	52,773	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. The transaction was conducted under a Rule 10b5-1 plan adopted August 12, 2025.

	/s/ Peter C. Farrell, Chairman emeritus	08/06/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)